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Background: PLB regulates SERCA activity and 
is thus a key regulator cardiac contractility.  
Results: We present the crystal structure of 
SERCA in complex with PLB at 2.8 Å resolution. 
Conclusion: PLB stabilizes a divalent cation-free 
conformation of SERCA with collapsed Ca2+ 
binding sites. We call the structure E2-PLB.  
Significance: The E2-PLB structure explains how 
PLB decreases Ca2+ affinity and depresses cardiac 
contractility. 
ABSTRACT 
P-type ATPases are a large family of enzymes 
that actively transport ions across biological 
membranes by interconverting between high 
(E1) and low (E2) ion-affinity states; these 
transmembrane transporters carry out critical 
processes in nearly all forms of life.  In striated 
muscle, the archetype P-type ATPase, SERCA 
(sarco(endo)plasmic reticulum Ca2+-ATPase), 
pumps contractile-dependent Ca2+ ions into the 
lumen of sarcoplasmic reticulum, which 
initiates myocyte relaxation and refills the 
sarcoplasmic reticulum in preparation for the 
next contraction.  In cardiac muscle, SERCA is 
regulated by phospholamban (PLB), a small 
inhibitory phosphoprotein that decreases the 
Ca2+ affinity of SERCA and attenuates 
contractile strength.  cAMP-dependent 
phosphorylation of PLB reverses Ca2+-ATPase 
inhibition with powerful contractile effects. 
Here we present the long sought crystal 
structure of the PLB/SERCA complex at 2.8 Å 
resolution.  The structure was solved in the 
absence of Ca2+ in a novel detergent system  
employing alkyl mannosides.   The structure 
shows PLB bound to a previously undescribed 
conformation of SERCA in which the Ca2+ 
binding sites are collapsed and devoid of 
divalent cations (E2-PLB).  This new structure 
represents one of the key unsolved 
conformational states of SERCA and provides a 
structural explanation for how 
dephosphorylated PLB decreases Ca2+ affinity 
and depresses cardiac contractility.  
Phospholamban (PLB)3, a single-span 
membrane protein of only 52 amino acids, is the 
principal membrane protein in the heart 
phosphorylated in response to β-adrenergic 
stimulation and a critical regulator of cardiac 
contractile strength (1).   In the dephosphorylated 
state, PLB decreases cardiac contractility by 
inhibiting the activity of the sarco(endo)plasmic 
reticulum Ca2+-ATPase (SERCA), an 110-
kilodaltaon membrane protein with 10 membrane-
spanning segments.  PLB inhibits SERCA activity 
by decreasing Ca2+ affinity at its two Ca2+ binding 
sites (I and II) located in the SR membrane, 
thereby attenuating SR Ca2+ filling and contractile 
force development.  Phosphorylation of PLB at 
Ser16 and Thr17 partially reverses PLB induced 
alterations in Ca2+ affinity, substantially 
augmenting contractility (2-4).   
Chemical cross-linking was used 
previously to localize the PLB binding site on 
SERCA to a groove formed between 
transmembrane helices M2, M4, M6 and M9 of 
the Ca2+ pump (5-9). In conjunction with 
functional assays, these cross-linking studies led 
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us to postulate that PLB binds to a unique Ca2+-
free (E2) state of SERCA and decreases the Ca2+ 
affinity of the enzyme through direct effects on the 
Ca2+ binding sites (5).  Recently, a gain-of-
function, cross-linkable PLB mutant, PLB4 
(N27A, N30C, L37A, V49G-PLB) (Fig. 1), was 
developed (10) and shown to bind to the Ca2+-
ATPase with exceedingly high affinity, 
comparable to or even greater than that of 
thapsigargin (TG), the well-known, irreversible 
Ca2+-ATPase inhibitor (11, 12).  Here, we took 
advantage of PLB4 to stabilize the Ca2+-free state 
of SERCA and to crystallize it in complex with 
PLB.  The 2.8 Å resolution structure, crystallized 
in nonyl maltoside, reveals a previously 
unresolved conformational state of the Ca2+ pump 
captured by PLB, which we define as E2-PLB. 
Importantly, the structure of E2-PLB is 
incompatible with Ca2+ (or Mg2+) binding to the 
enzyme, and confirms hypothesis that mutually 
exclusive binding of PLB and Ca2+ to SERCA is 
the mechanism by which PLB decreases apparent 
Ca2+ affinity (5). 
EXPERIMENTAL PROCEDURES 
Protein Preparation—SR vesicles 
sedimenting at 45,000 x g were isolated from 
rabbit back and hind leg muscle as described 
previously for cardiac SR vesicles (13).  SR 
vesicle pellets were extracted with 0.6 M KCl, 20 
mM MOPS (pH 7.0), resuspended in 0.25 M 
sucrose, 20 mM MOPS (pH 7.2), and stored 
frozen in small aliquots at -40°C at a protein 
concentration of 30 mg/ml.  Recombinant WT-
PLB and PLB4 were expressed and purified from 
Sf21 insect cells using anti-PLB monoclonal 
antibody  (2D12) affinity-chromatography as 
previously described (14).  Purified PLB was 
eluted from the column in 0.1% decyl maltoside or 
0.01% dodecyl maltoside (Anatrace), which in 
control experiments were determined to be optimal 
detergents for co-crystallization of PLB with the 
solubilized Ca2+-pump.  The purified, eluted PLB 
proteins were concentrated 100-fold with an 
Amicon concentrator, and then exhaustively 
dialyzed against 20 mM MOPS (pH 7.2), 20% 
glycerol, and 0.1 % decyl maltoside or 0.01% 
dodecyl maltoside.  The final working 
concentrations of PLB were 8-10 mg protein/ml. 
PLB was stored frozen at -40°C.  Protein 
concentrations were determined by the Lowry 
method. 
The Ca2+ pump suitable for crystallization 
was solubilized directly from SR vesicles without 
prior purification or extraction of SR vesicles with 
low concentrations of deoxycholate (15).  Thawed 
SR vesicles were diluted 1:1 to a protein 
concentration of 15 mg/ml in buffer containing 2% 
nonyl maltoside (Anatrace), 20% glycerol, 100 
mM MOPS (pH 7.0), 0.12 M sucrose, 80 mM 
KCl, 3 mM MgCl2, and 2.8 mM EGTA (final 
concentrations).  The samples were allowed to 
stand for 7 min at room temperature, then 
ultracentrifuged at 4°C at 100,000 rpm for 15 min 
in a Beckman TLA 100.1 rotor.  The supernatant 
was collected and PLB was added from the 
concentrated working solutions at a ratio of 0.14 
mg PLB/ 1.0 mg of solubilized SR vesicle protein, 
determined in control experiments to be a 
saturating concentration of PLB for inhibition of 
Ca2+-ATPase activity by lowering apparent Ca2+ 
affinity.   This amount of added PLB gave a molar 
ratio of PLB to SERCA of 2.9:1, as determined by 
quantitative immunoblotting (16).  Final volumes 
of mother liquors were adjusted by addition of 
20% glycerol to make the final EGTA 
concentration 2 mM and samples were stored at 
4°C.   Ca2+-ATPase prepared by this method (in 2 
mM EGTA) retained 95-100% of the initially 
solubilized activity for at least 3 weeks at 4° in the 
presence and absence of PLB (Fig. 2B). In pilot 
studies, the Ca2+ pump was solubilized from SR 
vesicles using other detergents, including C12E8 
and octyl glucoside.   Solubilization conditions 
were identical to that described above, using 2% 
detergent concentrations (Fig. 2B). 
Crystallization—One day after initial 
Ca2+-ATPase solubilization and addition of PLB, 
mother liquors were sedimented a second time by 
ultracentrifugation as described above.  Hanging 
drops were made by mixing 1 µl of the sedimented 
mother liquors with 1 µl reservoir solution (15 % 
glycerol, 17% (W/V) PEG-2000, 200 mM NaOAc, 
and 5 mM β-mercaptoethanol) and crystals were 
grown by vapor diffusion at 4°C.  Single crystals 
appeared within 2 weeks and grew to a final size 
of 150 x 100 x 50 µm within a month. Crystals 
were mounted using nylon fiber loops and flash 
cooled in liquid nitrogen with no additional cryo-
protectant.  
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Data Collection, Structure Solution and 
Refinement—The X-ray diffraction data were 
collected at Beamline 19-ID operated by the 
Structural Biology Center at the Advanced Photon 
Source within Argonne National Laboratory.  All 
diffraction data were collected at a wavelength of 
0.979 Å from a single crystal at 100°K. The 
crystal was formed from PLB4 added in decyl 
maltoside. The diffraction data was integrated and 
scaled using the program package HKL3000 (17). 
The structure was solved by molecular 
replacement using the individual protein domains 
of SERCA (PDB ID 2C8L) (18) as the search 
models. Solutions were found for the three 
cytoplasmic domains using Phaser (19), but no 
solution for the transmembrane region was 
obtained.  The initial model was constructed from 
the three cytoplasmic domains and used to 
calculate initial electron density maps into which 
the individual transmembrane helices were 
manually fit using the program Coot (version 
0.6.1(20)) and the connectivity of the M4 and M5 
helices to one of the cytoplasmic domains and the 
C-terminal transmembrane helix as points of 
reference. Helix M4 required fitting as two distinct 
sections and the connecting polypeptide was 
manually fit to the electron density in Coot.  The 
structure was subjected to interative rounds of 
model building and refinement using the program 
Refmac5 (21) and included the use of TLS tensors 
(22) to model the anisotropy of the individual 
domains and PLB.  In addition to SERCA and 
PLB, the final model includes one potassium ion 
and 2 non-covalently associated maltose 
molecules, for which the acyl chains were not 
visible in the electron density and hence have been 
modeled simply as maltose residues. Initial 
attempts to include a magnesium ion bound to site 
I in the transmembrane domain gave rise to a 
negative difference peak at 4.2 sigma in the Fo-Fc 
electron density map at the position of the 
modeled magnesium ion. Based on this 
information, combined with the lack of a positive 
peak in the Fo-Fc electron density map greater than 
2.7 sigma when the model is refined in the absence 
of magnesium and the fact that magnesium ions 
are not required for PLB cross-linking, we 
conclude that the PLB/SERCA complex lacks 
metal ions bound to the transmembrane metal 
sites. 
Ca2+-ATPase Assay—Ca2+-ATPase 
activity was determined colorimetrically by 
measuring inorganic phosphate release from ATP 
(16).  12 µg of solubilized Ca2+-ATPase protein 
(taken from mother liquors used for protein 
crystallization) were added to 1 ml of ATPase 
buffer containing 50 mM MOPS (pH 7.0), 3 mM 
MgCl2, 3 mM ATP, 100 mM KCl, 1 mM EGTA, 5 
mM NaN3, and 3 µg/ml A23187.  Ionized Ca2+ 
concentrations were set by addition of CaCl2.  
Some reaction tubes in addition contained 60-80 
µg of anti-PLB 2D12 antibody to reverse PLB 
inhibition of Ca2+-ATPase activity (23).  Reactions 
were conducted at 37°C and Ca2+-dependent 
activities are reported. KCa values designate Ca2+ 
concentrations at which Ca2+-ATPase is half-
maximally activated. 
Cross-linking—Cross-linking assays were 
conducted with solubilized Ca2+-ATPase protein 
reconstituted with PLB4 taken from mother 
liquors used for protein crystallization.  The Ca2+-
ATPase protein (12 µg) was added to 500 µl of 
buffer identical to that indicated above for 
determination of Ca2+-ATPase activity with 
omission of NaN3.  Cross-linking was conducted 
with 1 mM KMUS for 2 min at room temperature. 
Reactions were stopped with 7.5 µl of gel loading 
buffer containing 15% SDS and 100 mM 
dithiothreitol.  Samples were subjected to SDS-
PAGE and immunoblotting with the anti-PLB 
antibody, 2D12, for detection of PLB cross-linked 
to SERCA1a (skeletal muscle isoform) (Fig. 3C). 
Cross-linking of the canine cardiac isoform of the 
Ca2+ pump (SERCA2a) to N30C-PLB or PLB4 co-
expressed in insect cells was conducted identically 
as previously described (10) in 50 mM MOPS (pH 
7.0), 100 mM KCl, and 1 mM Ca2+: EGTA buffer 
in the presence or absence of 3 mM MgCl2 (Fig. 
6).  Cross-linking was conducted with 1 mM 
KMUS for one minute at room temperature. The 
results shown in Fig. 6 were conducted in the 
absence of ATP, however, similar results were 
obtained with inclusion of 3 mM ATP. Ki values 
indicate Ca2+ concentrations at which cross-linking 
is inhibited by 50%. 
RESULTS AND DISCUSSION 
Crystallization of the PLB/SERCA 
Complex—Crystallizing the novel Ca2+-free state 
of SERCA that binds PLB required that the 
solubilized enzyme be reconstituted with PLB in 
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the absence of Ca2+ (presence of EGTA).   
However, the Ca2+-ATPase is extremely labile and 
prone to denaturation when solubilized without 
Ca2+ (24, 25), and the detergents typically used for 
SERCA solubilization/crystallization (C12E8) (15, 
18, 26) and for PLB reconstitution with SERCA 
(C12E8 or octyl glucoside) (14, 27) had strong 
detrimental effects on Ca2+ affinity (Fig. 2A) 
and/or stability of the enzyme over time (Fig. 2B).  
For example, solubilizing SERCA in the absence 
of Ca2+ in C12E8 caused a 3-fold decrease in Ca2+ 
affinity and loss of enzyme activity with a t1/2 of 
~3 days at 4°C.  Octyl glucoside, on the other 
hand, did not affect Ca2+ affinity, but caused even 
more rapid denaturation of the enzyme, with a t1/2 
of less than one day at 4°C.   
 Consequently, a major challenge was to 
develop a new detergent system that would 
facilitate co-crystallization of SERCA 
reconstituted with PLB without denaturing the 
enzyme.  The nonionic detergent nonyl maltoside 
was ultimately selected for solubilization of 
SERCA as it had little effect on the Ca2+ affinity of 
the enzyme (KCa = 0.25 µM versus 0.21 µM in the 
absence of detergent) (Fig. 2A), and preserved 90-
100% of the solubilized Ca2+-ATPase activity for 
several weeks at 4°C (Fig. 2B).  SERCA 
solubilized in nonyl maltoside was then 
reconstituted with WT-PLB or PLB4 solubilized 
in decyl maltoside or dodecyl maltoside (shown 
with PLB4 solubilized in decyl maltoside in Fig. 
2B), detergents which also preserved SERCA 
catalytic activity for weeks at when stored at 4°C. 
Ca2+-ATPase assays in the newly developed 
detergent system show that WT-PLB and PLB4 
decreased the Ca2+ affinity of the solubilized 
enzyme by 2- and 5-fold, respectively, but had no 
significant effect on maximal ATPase activity 
measured at saturating Ca2+ concentrations (Fig. 
3B).  This alteration in the apparent Ca2+ affinity 
of SERCA is the hallmark of PLB inhibition (2, 
3).  As expected, addition of the 2D12 anti-PLB 
antibody (which mimics the effect of Ser16/Thr17 
phosphorylation of PLB (23)) largely reversed 
SERCA inhibition by WT-PLB and PLB4 (shaded 
dotted lines).   
Ca2+-dependent binding interactions 
between solubilized SERCA and PLB4 were also 
confirmed using chemical cross-linking.  Cross-
linking of residue N30C of PLB4 to Lys328 of 
SERCA with the heterobifunctional cross-linker 
KMUS (7, 10) was inhibited over the same Ca2+ 
concentration range (Ki = 1.6 µM) (Fig. 3C) as 
enzyme activation occurred (KCa = 1.4 µM) (Fig. 
3B).  This strongly suggests that PLB decreases 
the Ca2+ affinity of SERCA by disrupting Ca2+ 
binding (10) to the enzyme.  Fig. 3 further 
confirms that normal protein-binding interactions 
between PLB and SERCA were maintained in the 
newly developed detergent system, recapitulating 
results previously observed with intact SR vesicles
(16) or with ER membranes co-expressing the 
recombinant proteins (10).   The remarkable 
stability of Ca2+-free SERCA solubilized in nonyl 
maltoside is reported here for the first time. 
It should be mentioned that rabbit skeletal 
muscle SR vesicles were used as the source of the 
Ca2+ pumps in this study due to the high content of 
the ATPase protein in the SR membrane, making 
enzyme purification unnecessary (15) (Fig. 3D). 
(SERCA1a is highly homologous to the cardiac 
isoform, SERCA2a, and is regulated identically by 
PLB (6).  In addition, both WT-PLB and PLB4 
prepared in alkyl mannosides were predominantly 
multimeric on SDS gels; WT-PLB was mostly 
pentameric, and PLB4 ran mostly as pentamers 
and tetramers.  Boiling in 6% SDS prior to PAGE 
was required to destabilize these highly oligomeric 
forms of PLB (Fig. 3D), as observed previously 
with PLB purified in other detergents (14, 28).   
Crystallization trials with SERCA 
solubilized in nonyl mannoside were conducted at 
pH 7.0 in the presence and absence of PLB4, 
nucleotides (ADP and ATP), and Ca2+.  In the 
absence of Ca2+ (1 mM EGTA), SERCA crystals 
grew only in the presence of PLB4, and crystal 
growth was inhibited by increasing Ca2+ 
concentration, consistent with PLB stabilizing a 
Ca2+-free state of enzyme (5).  Addition of ADP or 
ATP to the mother liquors appeared to improve 
crystal quality in some trials; however, no electron 
density corresponding to nucleotide bound to 
SERCA was resolved in any of these crystal forms 
(data not shown). Crystallization trials were also 
conducted with WT-PLB, but the naturally 
occurring protein proved inferior to PLB4 in 
promoting SERCA crystal growth, presumably 
because its lower affinity for SERCA relative to 
PLB4 (10) makes it less efficient at stabilizing the 
pump for crystallization.   
PLB Binding Site on SERCA—The 
structure of E2-PLB at 2.83 Å resolution (Table 1) 
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shows PLB4 as an α-helix bound within a groove 
formed between transmembrane helices M2, M4, 
M6, and M9 of SERCA (Fig. 3A, magenta helix). 
Electron density corresponding to residues 21 to 
49 of the 52 amino acids comprising PLB (Fig. 1) 
was observed.  The α-helix extends uninterrupted 
from residue 21 in the cytoplasm to residue 49 in 
transmembrane domain.  The N-terminal twenty 
residues of PLB, which includes residues Ser16 and 
Thr17 that are subject to phosphorylation, are not 
visible in the electron density, but were 
nonetheless functional in the mother liquors as 
evidenced by the effects of the 2D12 antibody 
(Fig. 3B).  (Western blots of the re-solubilized 
crystals demonstrated that the PLB in E2-PLB was 
completely intact; PLB was detected at the 
appropriate mobility by the 2D12 antibody, which 
recognizes residues 7-14 of PLB, and by the 1F1 
antibody, which recognizes residues 1-5 of PLB). 
Residues 50-52 of PLB, predicted previously to 
remain alpha helical (9), were also unobserved in 
the electron density.  Consequently, it would 
appear that the central 29 residues of PLB form 
the majority of the stable inhibitory interactions 
with the Ca2+-ATPase. The E2-PLB structure 
confirms the location of the PLB binding site on 
the cardiac enzyme (SERCA2a) predicted 
previously by chemical cross-linking (5, 7-9).  The 
distances between specific amino acid residues of 
PLB and SERCA observed in the E2-PLB 
structure were expected to be consistent with the 
distances estimated by cross-linking (5-9, 16); 
however, we were surprised by how closely the 
experimental values agreed with those determined 
from the structure (Table 2), highlighting the 
utility of cross-linkers as molecular rulers.  
PLB Effects on the Ca2+ Binding Sites—
The signature effect of PLB is its ability to 
decrease the apparent Ca2+ affinity of SERCA, and 
the physical basis for this functional effect is now 
revealed in the E2-PLB structure.  The two high 
affinity Ca2+-binding sites (sites I and II) of 
SERCA, which are formed between 
transmembrane helices M4, M5, M6, and M8 near 
the cytoplasmic membrane interface (26), are both 
severely disrupted by PLB4 binding.  Fig. 4A 
shows significant unraveling of the “M4 kink” 
induced by PLB4, and the side chain of the Ca2+ 
gating residue, Glu309, now faces away from the 
Ca2+ binding sites (Fig. 4B).  The three main chain 
carbonyls on M4 contributing to site II are also 
displaced, making site II non-existent in our 
structure.   Site I is largely collapsed and would 
not support coordination of either Ca2+ or Mg2+ in 
the conformation induced by PLB4 binding (Fig. 
4B).  The contact of PLB4 with helices M4 and 
M6 appears to close site I for metal occupancy 
because the side chains of Asn768, Glu771, Asn796 
and Asp800 are all too close to accommodate the 
binding of a metal ion between their side chains 
and the peptide carbonyl oxygen of Ala305.  In 
particular, the distance geometry of residues 
Asn768 and Asn796 suggests the orientation of their 
side chain amide groups are switched from the 
orientations compatible with metal ion 
coordination in order to support hydrogen bonding 
interactions with the peptide carbonyl oxygen of 
Ala305 and the side chain of Glu771 (Fig. 4B).  
Thus, with PLB4 bound to SERCA, the Ca2+ pump 
adopts a conformation that is incompatible with 
either Ca2+ or Mg2+ binding to sites I and II.   The 
E2-PLB structure suggests that in order for the 
polar side chains and main chain carbonyls 
forming the Ca2+ binding sites to align properly, 
PLB4 must completely dissociate from its binding 
site in the groove between the M2, M4, M6, and 
M9.  Conversely, close spacing of M2 and M9 in 
the Ca2+-bound structure of SERCA (E1·Ca2) (26) 
appears to be incompatible with PLB binding to 
the PLB binding site defined in our structure.  This 
result confirms the cross-linking based theory of 
mutually exclusive binding of PLB and Ca2+ to 
SERCA (5-9), which has been controversial (29-
31). 
In the E2-PLB structure, Asn34 of PLB 
appears to be an important and highly organized 
region of contact specifically perturbing the Ca2+ 
binding sites (Fig. 5A).   Asn34 forms critical 
contacts with the main chain carbonyl oxygen of 
Gly801 (M6) and with the side chains of Thr805 
(M6) and Gln108 (M2) of SERCA.  Gln108, in turn, 
contacts the side-chain of Thr317, which may 
influence the positioning of the important Ca2+-site 
II ligand, Glu309 (5, 8).  The highly structured 
network of contacts with Asn34 of PLB appears to 
initiate a repositioning of residues 795-804 within 
the M6 helix; Asn796 now interacts with carbonyl 
oxygen of Ala305 and Ca2+ binding site I is 
collapsed (Fig. 4B).  These findings highlight the 
key role of Asn34 in the mechanism of PLB 
inhibition, and explain how the N34A mutation of 
PLB causes loss of PLB function (32), and how 
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the T795A, L802A, T805A, and F809A mutations 
in SERCA all partially attenuate PLB inhibition 
(33) .  Another SERCA mutation known to disable 
Ca2+ binding is G801V (34).  Our structure 
provides a plausible explanation for this 
phenomenon since a side chain at position 801 
would be impinged on by Val104 and reposition the 
M6 helix and its Ca2+ ligands, Asn796 and Glu800, in 
a manner similar to how Asn34 repositions the M6 
helix and these same Ca2+-ligands to collapse the 
Ca2+ binding site upon PLB binding (Fig 5A). 
Another functionally important residue of 
PLB, Leu31, is located one turn of the α-helix 
above Asn34, and only 3.7 Å away from Thr805 of 
SERCA.  Leu31 fits in a hydrophobic pocket 
defined by the side chains of Leu802, Ala806, and 
Phe809 in M6, and Trp932 and Leu939 in M9 (Fig. 5, 
A and B).  Like N34A, the L31A mutation 
completely disables PLB inhibition (32), whereas 
L31I preserves full functional activity (8).  This 
suggests that hydrophobic interactions of the 
proper size between residue 31 of PLB and 
M6/M9 of SERCA are required for proper 
positioning of Asn34 and SERCA inhibition.  The 
binding interface between PLB and SERCA is 
largely stabilized by hydrophobic interactions 
including Van der Waals contacts between carbon 
atoms (Fig. 5B, grey).  The contact surface buries 
between 1100-1200 Å2 and about 40% of the 
available surface area of PLB4 between residues 
21-49.  There are only a few polar contacts, 
specifically between the amide nitrogen of Asn34 
(blue) and the main chain carbonyl of Gly801 and 
the amide carbonyl of Gln108 and side chain of 
Thr805 (all in red, Fig. 5B).  It is particularly 
interesting that the extensive polar contacts 
surrounding Asn34 takes place in the context of a 
particularly hydrophobic surface, which likely 
enhances their impact on SERCA function. 
Manipulation of side chain contacts 
between PLB and SERCA can enhance as well as 
attenuate PLB inhibitory function, explaining the 
superinhibitory nature of PLB4.  For example, the 
N27A mutation (35) near the cytoplasmic 
membrane interface of PLB would allow PLB4 to 
bind more tightly to SERCA because the smaller 
side chain of Ala fits more snugly into the 
hydrophobic cleft between Phe809 (M6) and Trp932 
(M9), where the distances between the methyl side 
chain of Ala and the two aromatic side chains are 
only 3.6-3.9 Å  (Fig. 5B).  Ala substitution at 
Leu37 in the bilayer interior (32, 36) is likewise 
expected to attenuate steric clash between the long 
alkyl side chain of Leu37 and the hydrophobic side 
chains of Ile103 and Val104 at M2 (Fig. 5B). The 
more compact side chain of Ile37 appears to fit the 
available space within this hydrophobic pocket 
better than Leu37, which would also explain the 
superinhibitory effect of the L37I mutation (37).  
At the C-terminal end of PLB4 at the luminal 
membrane interface, residue 49 of PLB is very 
close to Val89 (M2) (Table 2) (6, 9).  The smaller 
side chains of Ala or Gly at this position appears 
to reduce steric hindrance with Val89 (Fig. 5B), 
explaining the superinhibitory effects of the V49A 
and V49G mutations in PLB (9).  Thus PLB4 
inhibitory function is augmented by the additive 
effects of the N27A, L37A, and V49G mutations, 
each of which optimizes the packing interactions 
between PLB and hydrophobic residues in the 
Ca2+-ATPase.  This observation also explains why 
PLB4 binds to SERCA with an affinity greater 
than that of TG (10), which binds with sub-
nanomolar affinity to the Ca2+ pump (11, 12).  
It should be pointed out that the above 
interpretation of how the point mutations in PLB4 
would alter PLB interactions with the Ca2+-
ATPase and enhance its inhibitory function are 
based upon the assumption that WT-PLB would 
stabilize the enzyme in a nearly identical state as 
that captured by PLB4.  Indeed, the structure of 
SERCA with PLB4 bound suggests that the point 
mutations in PLB4 would have only localized 
structural affects relative to WT-PLB.  Moreover, 
the distances between specific amino acids of PLB 
and SERCA determined by cross-linking are 
nearly identical, whether determined with PLB 
molecules of normal or superinhibitory strength, 
including cross-linking of WT-PLB in native 
human SR vesicles (16). The distances determined 
by cross-linking with the normal strength PLB 
mutants reported in Table 2 are in close agreement 
with the distances between the same residues 
observed in the PLB4/SERCA crystal structure. 
Therefore, the crystal structure of SERCA with 
WT-PLB bound is likely to be very similar to the 
PLB4 bound structure.   
Multimeric Nature of PLB—PLB is a 
pentamer of identical monomers (28, 38, 39).  It 
has been proposed for some time that there is a 
dynamic equilibrium between PLB pentamers and 
monomers in the SR membrane (40, 41), and that 
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the PLB monomer is responsible for binding to 
SERCA and inhibiting it (32, 36).  Residues Leu37, 
Ile40, Leu44, Ile47, and Leu51 of PLB form the 
Leu/Ile zipper (40) that stabilizes the non-
inhibitory PLB pentamer (41); Ala substitution at 
any of these residues promotes pentamer 
dissociation, an increase in PLB monomers, and 
increased enzyme inhibition (32, 36).   It was also 
suggested that PLB has two distinct functional 
faces located on opposite sides of the 
transmembrane helix: the Leu/Ile zipper face 
which when PLB is bound to SERCA points away 
from the enzyme and is involved only in PLB 
pentamer formation, and the inhibitory face which 
comes in direct contact with the Ca2+-ATPase and 
mediates enzyme inhibition (32).  Here we find 
that this idea is indeed correct for the Ile arm of 
the zipper; the heptad repeat of Ile zipper residues 
40 and 47 is oriented away from the Ca2+-pump 
when the PLB monomer is bound to the enzyme 
(Figs. 4A and 5C, magenta).  In contrast, on the 
Leu arm of the zipper, both Leu37 (mutated to Ala 
in PLB4) and Leu 44 make direct contact with the 
Ca2+ pump at M2 (at Ile103 and Val104, and at Leu96, 
respectively) (Figs. 4A and 5B), consistent with 
the dual role of these two zipper residues in both 
pentamer formation and enzyme inhibition (37).  
At other positions along the transmembrane helix 
of PLB, residues Phe35, Ile38, Cys41, Leu42, Ile45, 
and Ile48 all make direct contact with non-polar 
residues in several transmembrane helices of 
SERCA (Fig. 5, B and C), contributing to the high 
binding affinity of the PLB monomer for the Ca2+-
ATPase (10,16). 
It should be noted that the mobility forms 
of WT-PLB and PLB4 observed on SDS gels are 
quite different.  Whereas WT-PLB ran 
predominately as pentamers with a small amount 
of monomers, all five mobility forms of PLB4 
were observed (Fig. 3D).  Prior to boiling in 6% 
SDS, pentamers and tetramers predominated with 
PLB4; after boiling in SDS, monomers and dimers 
were the main mobility forms.  The significance of 
this observation became apparent when we 
discovered additional weak electron density 
embedded in the membrane near PLB4 in all of 
our datasets (Figs. 3A, 4A, 5A, and 5C, yellow 
helices).  The electron density is consistent with a 
14 amino acid-long α-helix (yellow) that is in 
direct contact with the outer face of the PLB4 
monomer directly bound to SERCA (magenta), 
but this second helix does not contact SERCA. 
The nature of the observed electron density for this 
second helical region (PLB (chain C) in Table 1) 
indicates significant conformational freedom, low 
occupancy, or both.   This density was able to 
accommodate the PLB4 sequence, but was not 
compatible with the sarcolipin (SLN) sequence 
register, and PLB4 dimers were also present in our 
re-solubilized crystals run on SDS-PAGE (data not 
shown).  Therefore, the extra helix is most likely 
attributable to a second PLB4 molecule bound to 
PLB but not physically in contact with SERCA. 
Residues Phe32, Cys36, Leu39, Ile40, Leu43 and Ile47 
of PLB4 appear to be interacting with residues 
Cys30, Ile33, Cys36, Ala37, and Ile40 of the second 
PLB4 molecule, which includes the two Ile zipper 
residues (40 and 47) that help to stabilize PLB 
pentamers (Figs. 4A and 5C).   
Although PLB4 is largely pentameric or 
tetrameric when purified in non-denaturing 
detergents, the crystal structure clearly indicates 
that the PLB monomer forms the important 
contact surface between PLB4 and SERCA (Fig. 
5C).  No PLB4 pentamers or tetramers attached to 
SERCA were identified in any of the datasets. 
Therefore, a reversible equilibrium (32, 36) 
between pentamer-tetramers and monomer-dimers 
of PLB4 must exist in order to allow regulatable 
inhibition of SERCA activity over the range of 
Ca2+ concentrations depicted in Fig. 3, B and C.  
Consistent with this, at the molar ratio of PLB to 
SERCA used for crystal formation (2.9 to 1), there 
are sufficient dimers, but insufficient pentamers or 
tetramers, to allow complete inhibition of SERCA 
at the lower Ca2+ concentrations assayed (Fig. 3B).  
Pentamer formation by monomers released from 
SERCA thus appears to aid in complete reversal of 
enzyme inhibition at saturating Ca2+ concentration 
(Fig. 3, A and C), as recently demonstrated using 
intact SR vesicles from human hearts (16).  
The structure is therefore consistent with 
there being an equilibrium between PLB/SERCA 
heterodimers, free PLB monomers, and PLB 
pentamers in the SR membrane, with reversible 
exchange of PLB protomers between the different 
oligomeric states.  Even though PLB4 is strongly 
bound to the enzyme in the absence of Ca2+, there 
is still a reversible equilibrium with PLB 
continuously associating and dissociating from 
SERCA.  During this rapid exchange, the 
collapsed Ca2+ binding sites can briefly re-form, 
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providing an opportunity for a Ca2+ to bind to the 
enzyme.  High Ca2+ concentrations shift the 
binding equilibrium towards PLB dissociation, 
which is aided by the fact that the free PLB 
molecules can oligomerize into stable 
homopentamers. 
The Conformation of SERCA that Binds 
PLB—The structure of SERCA in the 
PLB4/SERCA complex is distinct from the 
previously determined structures of SERCA in the 
E2 (low Ca2+ affinity) or E1 (high Ca2+ affinity) 
state (26).  The Ca2+-ATPase in our structure is 
globally similar to E1·Ca2 in the overall spacing of 
the transmembrane helices and in the open 
arrangement of the cytoplasmic headpiece (Fig. 
3A).  However, unlike E1·Ca2, the M1 helix in the 
PLB4–bound Ca2+ pump structure is positioned 
lower in the membrane, and is distinctly bent at 
Leu60.  In this position, the “M1 sliding door” that 
controls the opening to the purported Ca2+ access 
channel is open, exposing a number of negatively 
charged residues that lead to the Ca2+ binding sties 
(26, 42).  An open Ca2+ access channel, as 
observed in our structure, is a key feature of the 
enzyme in the E2 state (26, 42).  In addition, the 
metal-free Ca2+ binding sites in the PLB4/SERCA 
complex more closely resemble E2 than E1 (24).  
PLB4 contacts with M4 and M6 appear to stabilize 
hydrogen bonding between residues Asn796, 
Asn768, Glu771, and the main-chain carbonyl of 
Ala305 (Fig. 5D).  Although the spatial 
arrangement is somewhat different, conceptually 
similar interactions are observed in the metal-free 
Ca2+ binding sites in the E2-TG structure (24 and 
Fig. 5D).  The apparent hydrogen bonding at the 
Ca2+ binding sites is consistent with the enzyme 
being protonated; it is generally accepted that 
protons stabilize the empty Ca2+ binding sites in 
the E2 state (26, 42).   Therefore, PLB stabilizes a 
structure in which the Ca2+ binding sites are 
collapsed and appear to be protonated, and we 
define this structure as E2-PLB.   
While this manuscript was in preparation, 
two separate groups (Toyoshima et al. (43) and 
Winther et al. (44) published crystal structures of 
Ca2+-free SERCA stabilized by very high 
concentrations of MgSO4 (40-75 mM) (referred to 
hereafter as E1·Mg (43)).  The structures were 
nearly identical, and both had sarcolipin (SLN) 
bound.  SLN is a 31 amino acid, skeletal-muscle 
"homologue" of PLB with ambiguous function 
(Fig. 1).  Since the contacts between SLN and 
SERCA observed in the E1·Mg structures were 
similar to PLB/SERCA interactions determined 
previously by cross-linking (5-9), both groups 
postulated that the E1·Mg state they crystallized is 
the same state that binds PLB.  On a global scale, 
PLB and SLN appear to bind to similar 
conformations of the transmembrane domain of 
SERCA, albeit with distinct orientations of the 
cytoplasmic domains.  However, at the molecular 
level, notable structural differences in their 
respective transmembrane domains support that 
PLB stabilizes a distinct conformation of SERCA. 
Specifically, the Ca2+ binding sites in the E1·Mg 
structures are partially formed and have a 
distinctly E1-like appearance.  On the other hand, 
in the metal-free E2 state that binds PLB, the Ca2+ 
binding sites are completely collapsed with 
interactions more similar to E2 than E1.  In 
contrast to claims in these two recent papers (43, 
44), the effects of SLN on Ca2+-ATPase activity 
are different from those of PLB and remain 
controversial—no effect, Ca2+ affinity effects, Vmax 
effects, and uncoupling effects of SLN have all 
been reported (27, 45-47).  In detailed comparative 
studies, two separate groups recently concluded 
that SLN and PLB regulate SERCA by completely 
different mechanisms (27, 45).  In one study, SLN 
effects on Ca2+-ATPase activity were attributed to 
the unique C-terminal tail of SLN (containing 
Arg27 and Tyr31), which is not found in PLB (27). 
In the second study, SLN had no effect on Ca2+-
ATPase activity, but instead uncoupled Ca2+ 
transport from ATP hydrolysis, and SLN 
continued to interact with SERCA in the presence 
of Ca2+ (45), in contrast to PLB, which dissociates 
from SERCA in the presence of Ca2+ (5). 
Therefore, unlike the recent SLN-bound E1·Mg 
structures, the PLB induced structural changes in 
SERCA observed presently have clear mechanistic 
implications that are consistent with PLB effects 
on Ca2+-affinity (2).  
The physiological significance of the 
E1·Mg state of SERCA is also worth discussion. 
In both studies mentioned above (43, 44), the 
structures were solved with the Ca2+-free enzyme 
solubilized in C12E8, a condition known to cause 
irreversible enzyme inactivation (24, 25) (Fig. 2). 
It seems likely that at the high concentrations of 
MgSO4 utilized, Mg2+ was acting as a surrogate 
for Ca2+, thereby preventing enzyme denaturation.  
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However, whether the E1·Mg state occurs at 
physiological Mg2+ concentration is unknown, and 
the functional role of the putative state is unclear.  
Toyoshima et al. (43) concluded that E1·Mg is an 
obligate intermediate in the catalytic cycle of 
SERCA and that Mg2+ binding accelerates Ca2+ 
binding by reducing the energy required for 
formation of E1·Ca.  On the other hand, Winther 
et al. (44) concluded the opposite, that Mg2+ 
binding to the “low affinity Mg2+ sites” actually 
retards SERCA activation by Ca2+.   
Cross-linking of PLB to SERCA can be 
used to test whether Mg2+ is required for PLB 
binding, and whether Mg2+ affects SERCA Ca2+ 
affinity, as postulated by Toyoshima et al. (43) 
and Winther et al. (44).  Using both N30C-PLB, 
which alters Ca2+ affinity like WT-PLB, and 
PLB4, which supershifts Ca2+ affinity, we found 
that physiological concentrations of Mg2+ (3 mM) 
had no effect on the extent of PLB cross-linking to 
SERCA, and only minor effects on Ki values for 
Ca2+ inhibition of PLB cross-linking, thus 
reflecting minimal effects of Mg2+ on Ca2+ affinity 
of the enzyme (Fig. 6).  Clearly, E1·Mg is not the 
state required for PLB binding, as was recently 
proposed (45, 46).  Moreover, based upon our 
crystal structure and cross-linking results (Fig. 6), 
we conclude that the E1·Mg state of SERCA 
obtained at 40-75 mM MgSO4 (45, 46) does not 
exist at physiological Mg2+ concentration (~ 3 
mM). 
In conclusion, we have determined the 
crystal structure of PLB4 bound to a unique metal-
free E2 state of SERCA, one of the critical 
outstanding conformational states of the Ca2+-
ATPase remaining to be solved (5, 10).  
Interpreted in light of the extensive biochemical 
and physiological studies on PLB (2, 3), the new 
SERCA structure has allowed us to explain how 
through direct effects on Ca2+ affinity, 
dephosphorylated PLB inhibits SERCA activity 
and decreases contractility of the heart.  Co-
crystallization of PLB4 with SERCA was achieved 
using a newly developed detergent system 
specifically designed to maintain SERCA catalytic 
activity and normal regulation by PLB after 
solubilization in the absence of Ca2+.  Using this 
new system, it should be possible to crystallize 
SERCA with other forms of PLB, including WT-
PLB, and ultimately to resolve the binding site for 
the N-terminus of PLB on the Ca2+ pump, which 
has remained problematical (6, 7, 48).  The N-
terminal domain of PLB is of particular 
physiological interest because β-adrenergic-
receptor stimulated phosphorylation of PLB at 
Ser16 and Thr17 is fundamental to the mechanism 
by which PLB regulates myocardial contractility 
(1, 4).  
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Table 1.  Data collection and refinement statistics 
SERCA/PLB4 
Data Collection 
Space group P212121 
Cell dimensions 
     a, b, c (Å) 61.59, 93.09, 316.4 
     Cell angles (a, b, g °) 90.0, 90.0, 90.0 
Resolution (Å) 50.0-2.83 (2.89-2.83) 
Rmerge(%) 8.4 (49.2) 
I / s<I> 13.2 (2.0) 
Completeness (%) 97 (97) 
Redundancy 5.5 (4.5) 
Wilson B-value (Å2) 88.5 
Refinement 
Resolution (Å) 50.0-2.83 
No. reflections 42925 
Rwork / Rfree(%) 23.9/28.4 
No of atoms 
     Protein 7861 
     Ligand/ion 47 
B-factors (Å2) 
     Serca (chain A) 89.6 
     PLB (chain B) 140.2 
     PLB (chain C) 183.4 
     Ligand/ion 85.5 
R.m.s deviations 
     Bond lengths (Å) 0.009 
     Bond angles  (°) 1.20 
Ramachandran Plot 
     Core 88.9 
     Allowed 11.0 
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Table 2.  Distances between residues of PLB 
and SERCA determined by cross-linking (X-
link) versus x-ray diffraction (Crystal) 
Distance (Å) 
PLB SERCA   X-link Crystal  Ref. 











N30C K328 14–16 17 7 
L31C T317C 10 10 8 
V49C V89C 0–5 5 6,9 
M50C V89C 10 ND 9 
L52C V89C 5 ND 9 
Cross-linking distances between residues of PLB and 
SERCA were determined after co-expression of 
selected mutants of PLB with SERCA2a (5, 7-9) or 
SERCA1a (6) in microsomal membranes, or with 
native PLB and SERCA2a in human cardiac SR 
vesicles (16). Cross-linking was conducted with homo- 
or heterobifunctional cross-linking reagents (5, 7-9, 16) 
or with copper phenanthrolene (6). The distances in 
the PLB4/SERCA crystal structure were determined by 
measuring from the β-carbon of the PLB residue to the 
closest side chain atom of the corresponding SERCA 
residue (native protein).  For V49G in PLB4 the 
distance was measured from the α-carbon of Gly49.  
ND, not determinable. *The distance measurement 
between K27 and K328 was estimated by 
computational mutation of A27 to K and selecting side 
chain rotomers compatible with the local structure for 
both K27 and K328, then measuring the closest 
approaches for the side chains. 
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FIGURE LEGENDS 
FIGURE 1.  Amino acid sequences of PLB4 and WT-PLB (canine isoforms), and rabbit SLN.  
Cytoplasmic and transmembrane domains are shown as well as the phosphorylated residues Ser16 and 
Thr17 of PLB.  Mutations in PLB4 are shaded in blue.  Amino acid residues common to both PLB and 
SLN are shaded in yellow.  
FIGURE 2. Effect of detergent solubilization of SERCA on apparent Ca2+ affinity (A) and Ca2+-
ATPase stability over time (B). Mother liquors were prepared from rabbit skeletal SR vesicles in buffer 
containing 2% detergent concentrations and 2 mM EGTA as described under EXPERIMENTAL 
PROCEDURES.  A, apparent Ca2+ affinity (KCa) of the solubilized Ca2+-ATPase was determined 
immediately after membrane solubilization by measuring Ca2+ activation of ATP hydrolysis.  Results are 
expressed as percentage of the maximal Ca2+-ATPase activity obtained for each detergent tested: NM 
(nonyl glucoside), OG (octyl glucoside), DM (decyl maltoside), DDM (dodecyl maltoside).  Control 
membranes (Con) were not treated with detergent. KCa values (µM) were 0.21 ± 0.005 (Con), 0.25 ± 0.02 
(NM), 0.23 ± 0.02 (OG), 0.63 ± 0.02 (C12E8), 0.29 ± 0.01 (DM), and 0.40 ± 0.02 (DDM).  Mean ± S. E. 
from 4 - 8 determinations.  B, enzyme stability of SERCA was monitored after storage of the mother 
liquors in different detergents at 4 °C for the times indicated. At the designated times of storage, aliquots 
were taken for assay of Ca2+-ATPase activity (µmol Pi/mg protein/h) at saturating Ca2+ concentration (50 
µM Ca2+).  NM + PLB4 designates SERCA solubilized in NM reconstituted with PLB in DM, an optimal 
condition for crystal formation. Shown is one representative experiment, which was repeated at least three 
times for all the different detergents with similar results. 
FIGURE 3.  Crystal structure and functional characterization of the PLB4/SERCA complex.  A, a 
ribbon model of the complex between SERCA and PLB4. In SERCA the cytoplasmic headpiece consists 
of actuator (A) (grey), phosphorylation (P) (gold), and nucleotide-binding (N) (green) domains. The 
transmembrane domain helices of SERCA are colored cyan, except for M4, which is colored blue. The 
bound PLB4 molecules are colored magenta (chain B) and yellow (chain C) (Table 1). The figure was 
generated using PyMOL (The PyMOL Molecular Graphics System, Version 1.5.0.4 Schrödinger, LLC.). 
B, Ca2+-ATPase activity of nonyl maltoside-solubilized SERCA alone and after reconstitution with 
purified, solubilized WT-PLB or PLB4.  Activity was measured in the presence and absence of the anti-
PLB monoclonal antibody, 2D12.  KCa values (µM) for Ca2+ activation of ATP hydrolysis were:  No PLB, 
0.26 ± 0.01; WT-PLB, 0.62 ± 0.03, and 0.35 ± 0.02 (+ 2D12); PLB4, 1.38 ± 0.07, and 0.53 ± 0.03 (+ 
2D12).  Means ± S. E. from 3-6 determinations.  C, anti-PLB immunoblot showing Ca2+ effect on cross-
linking of PLB4 to SERCA with KMUS under the same conditions used for determination of Ca2+-
ATPase activity.  Ki value (µM) for Ca2+ inhibition of cross-linking was 1.60 ± 0.16.  Mean ± S. E. from 6 
determinations.  D, coomassie-blue stained gel showing SERCA solubilized from rabbit skeletal muscle 
SR membranes and WT-PLB and PLB4 purified in decyl maltoside (± boil).  10 µg of membrane protein 
were electrophoresed per gel lane. 
FIGURE 4.  Binding of PLB4 to the transmembrane domain of SERCA. A, a view of PLB4 bound to 
SERCA roughly orthogonal to that in Figure 3A including the side chains of PLB4 interacting with the 
transmembrane domain; color scheme is identical to Figure 3A. B, a horizontal section of the SERCA 
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transmembrane domain showing the interaction area of PLB4 in the proximity of the Ca2+-binding sites – 
color scheme is identical to Figure 3A. Critical side chains are labeled and displayed, as are the nearby 
transmembrane helices. The dotted lines and numerical values indicate the distances between potential 
hydrogen bond donors and acceptors. Figure generated using PyMOL. 
FIGURE 5.  Critical interactions at the interface between SERCA and PLB4.  A, a horizontal section 
of the SERCA transmembrane domain centered near the key inhibitory residue Asn34 of PLB4.  The color 
scheme is identical to Fig. 4A. Key residues at the interaction surface are labeled, as are the individual 
transmembrane helices in this region.  The dotted line indicates inferred hydrogen bonding between donor 
and acceptor atoms and the numerical value indicates the distance between atoms potentially sharing 
hydrogens. B, a “peeled” surface view of the interaction surface between PLB4 and SERCA. For this 
figure, PLB4 was rotated 180 degrees in the vertical plane and translated to the right hand side of this 
figure in order to expose the interacting surfaces and their chemical character.  The color scheme utilizes 
“atom-type” coloring (blue for nitrogen, red for oxygen, yellow for sulfur and green for carbon atoms not 
involved in the contact surface between PLB4 and SERCA). Carbon atoms in amino acids residing either 
in PLB4 or in SERCA that have at least one atom at the contact surface are colored grey. Amino acid 
residues that form the contact surface are labeled. C, the original figure-of-merit sA-weighted 2Fo-Fc 
(blue) and Fo-Fc (green) electron density maps for PLB4 bound to the transmembrane domain of SERCA 
generated prior to their inclusion in the model, superimposed on the final refined coordinates for the 
complex. D, structural super-positioning of the PLB4/SERCA complex (cyan and magenta ribbons for 
SERCA and PLB4) with that of the Ca2+-free E2 complex stabilized by TG (green ribbons, RCSB code 
1IWO (24)). The structures were super-imposed utilizing the C-alpha atoms of residues 750-990. Key 
residues involved in Ca2+-binding are labeled, as is Ile38 of PLB4. 
FIGURE 6.  Lack of effect of Mg2+ on PLB cross-linking.  A, autoradiograph showing cross-linking of 
N30C-PLB or PLB4 to SERCA2a expressed in insect cell membranes.  Cross-linking was conducted with 
KMUS over a range of Ca2+ concentrations in the presence and absence of 3 mM MgCl2. B, quantified 
results plotted as percentage of maximal cross-linking determined at zero Ca2+ concentration.  Mg2+ had 
no effect on maximal cross-linking.  Ki values (µM) for Ca2+ inhibition of cross-linking of N30C-PLB to 
SERCA were 0.37 ± 0.05 and 0.46 ± 0.07 in the absence and presence of Mg2+, respectively.  Ki values 
for Ca2+ inhibition of PLB4 cross-linking were 1.52 ± 0.06 and 1.70 ± 0.10, respectively.  Means ± S. E. 
from 3-5 determinations. 
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